{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:58:41Z","timestamp":1781351921874,"version":"3.54.1"},"reference-count":11,"publisher":"Informa Healthcare","issue":"sup3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1185\/030079905x46278","type":"journal-article","created":{"date-parts":[[2006,5,18]],"date-time":"2006-05-18T23:19:55Z","timestamp":1147994395000},"page":"S8-S12","source":"Crossref","is-referenced-by-count":6,"title":["Part II: Clinical efficacy and tolerability of zolmitriptan orally disintegrating tablet in the acute treatment of migraine"],"prefix":"10.1185","volume":"21","author":[{"given":"Elizabeth W.","family":"Loder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Dowson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egilius L. H.","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2005,7,12]]},"reference":[{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701041"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.5.1210"},{"key":"CIT0004","first-page":"1219","volume":"49","author":"Solomon GD","year":"1997","journal-title":"5 mg zolmitriptan for the acute treatment of migraine. Neurology"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00017.x"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200013030-00007"},{"key":"CIT0007","first-page":"120","volume":"44","author":"Loder E","year":"2004","journal-title":"Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebocontrolled study. Headache"},{"issue":"1","key":"CIT0008","first-page":"236","volume":"60","author":"Rapoport A","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"CIT0009","first-page":"S20\u2013S26","volume":"39","author":"Lipton RB","year":"1999","journal-title":"Headache"},{"key":"CIT0010","first-page":"19","volume":"43","author":"MacGregor EA","year":"2003","journal-title":"Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00319.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418150-00007"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079905X46278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T08:45:28Z","timestamp":1481618728000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079905X46278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":11,"journal-issue":{"issue":"sup3","published-online":{"date-parts":[[2005,7,12]]},"published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1185\/030079905X46278"],"URL":"https:\/\/doi.org\/10.1185\/030079905x46278","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}